Brighton Jones’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.87M Sell
20,666
-1,687
-8% -$98.7K 0.03% 332
2026
Q2
$857K Sell
22,353
-196
-0.9% -$5.14K 0.02% 565
2026
Q1
$479K Buy
+22,549
New +$451K 0.01% 716
2025
Q4
– Sell
-22,349
Closed -$261K – 882
2025
Q3
$261K Sell
22,349
-338
-1% -$4.41K 0.01% 863
2025
Q2
$263K Buy
+22,687
New +$207K 0.01% 778
2024
Q2
– Sell
-5,395
Closed -$202K – 666
2024
Q1
$202K Buy
+5,395
New +$237K 0.01% 578
2022
Q1
– Sell
-1,459
Closed -$217K – 551
2021
Q4
$217K Buy
1,459
+13
+0.9% +$1.99K 0.01% 474
2021
Q3
$211K Hold
1,446
– – 0.01% 445
2021
Q2
$283K Buy
1,446
+5
+0.3% +$905 0.01% 361
2021
Q1
$261K Buy
+1,441
New +$249K 0.02% 340

Other funds holding TXG

Brighton Jones's TXG Position: Q3 2026 in Review

Brighton Jones reduced its 10x Genomics (TXG) stake by 7.5% in Q3 2026, selling an estimated $98.7K and leaving 20,666 shares worth $1.87M. The position accounts for 0.03% of the portfolio, ranked #332.

Brighton Jones first reported a position in TXG in Q1 2021 and has held it in 10 quarters since. 377 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Brighton Jones held 20,666 shares of 10x Genomics worth $1.87M as of Q3 2026.
  • Brighton Jones sold 1,687 10x Genomics shares in Q3 2026, an estimated $98.7K.
  • 10x Genomics made up 0.03% of Brighton Jones's portfolio in Q3 2026, its #332 holding.
  • Brighton Jones first reported a position in 10x Genomics in Q1 2021 and has held it in 10 quarters since.
  • 377 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.